129 related articles for article (PubMed ID: 26287187)
1. Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma.
González-Alonso P; Chamizo C; Moreno V; Madoz-Gúrpide J; Carvajal N; Daoud L; Zazo S; Martín-Aparicio E; Cristóbal I; Rincón R; García-Foncillas J; Rojo F
Int J Mol Sci; 2015 Aug; 16(8):19447-57. PubMed ID: 26287187
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer.
Dey P; Gadewal N; De A
Int J Biol Macromol; 2023 Jul; 242(Pt 2):124765. PubMed ID: 37156315
[TBL] [Abstract][Full Text] [Related]
3. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
Roy-Chowdhuri S; de Melo Gagliato D; Routbort MJ; Patel KP; Singh RR; Broaddus R; Lazar AJ; Sahin A; Alvarez RH; Moulder S; Wheler JJ; Janku F; Gonzalez-Angulo AM; Chavez-MacGregor M; Valero V; Ueno NT; Mills G; Mendelsohn J; Yao H; Aldape K; Luthra R; Meric-Bernstam F
Am J Clin Pathol; 2015 Nov; 144(5):713-21. PubMed ID: 26486734
[TBL] [Abstract][Full Text] [Related]
4. KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR.
de Macêdo MP; de Melo FM; Lisboa BC; Andrade LD; de Souza Begnami MD; Junior SA; Ribeiro HS; Soares FA; Carraro DM; da Cunha IW
Exp Mol Pathol; 2015 Jun; 98(3):563-7. PubMed ID: 25835782
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
6. HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1.
Kumagai T; Tomita Y; Nakatsuka SI; Kimura M; Kunimasa K; Inoue T; Tamiya M; Nishino K; Susaki Y; Kusu T; Tokunaga T; Okami J; Higashiyama M; Imamura F
Thorac Cancer; 2018 Apr; 9(4):466-471. PubMed ID: 29473311
[TBL] [Abstract][Full Text] [Related]
7. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
[TBL] [Abstract][Full Text] [Related]
8. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
9. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
10. Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients.
Ananiev J; Aleksandrova E; Skerleva D; Gulubova M; Chokoeva A; Lotti T; Wollina U; Tchernev G; Kontić M; Stojšić J
Wien Med Wochenschr; 2015 Aug; 165(15-16):315-21. PubMed ID: 26208475
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras AK; Kalogeras KT; Dimopoulos MA; Wirtz RM; Dafni U; Briasoulis E; Pectasides D; Gogas H; Christodoulou C; Aravantinos G; Zografos G; Timotheadou E; Papakostas P; Linardou H; Razis E; Economopoulos T; Kalofonos HP; Fountzilas G;
Br J Cancer; 2008 Dec; 99(11):1775-85. PubMed ID: 18985033
[TBL] [Abstract][Full Text] [Related]
12. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.
Wen W; Chen WS; Xiao N; Bender R; Ghazalpour A; Tan Z; Swensen J; Millis SZ; Basu G; Gatalica Z; Press MF
J Mol Diagn; 2015 Sep; 17(5):487-95. PubMed ID: 26320869
[TBL] [Abstract][Full Text] [Related]
14. Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples.
Cortes U; Guilloteau K; Rouvreau M; Archaimbault C; Villalva C; Karayan-Tapon L
Exp Mol Pathol; 2015 Oct; 99(2):207-11. PubMed ID: 26163758
[TBL] [Abstract][Full Text] [Related]
15. Highly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR method.
Takase Y; Usui K; Shimizu K; Kimura Y; Ichihara T; Ohkawa T; Atsumi J; Enokida Y; Nakazawa S; Obayashi K; Ohtaki Y; Nagashima T; Mitani Y; Takeyoshi I
PLoS One; 2017; 12(2):e0171225. PubMed ID: 28152008
[TBL] [Abstract][Full Text] [Related]
16. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
[TBL] [Abstract][Full Text] [Related]
17. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
18. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
19. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract][Full Text] [Related]
20. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
Ross JS; Wang K; Gay LM; Al-Rohil RN; Nazeer T; Sheehan CE; Jennings TA; Otto GA; Donahue A; He J; Palmer G; Ali S; Nahas M; Young G; Labrecque E; Frampton G; Erlich R; Curran JA; Brennan K; Downing SR; Yelensky R; Lipson D; Hawryluk M; Miller VA; Stephens PJ
Clin Cancer Res; 2014 Jan; 20(1):68-75. PubMed ID: 24192927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
